SEARCH

SEARCH BY CITATION

References

  • 1
    Hedner U, Glazer S, Pingel K et al. Successful use of recombinant factor VIIa in a patient with severe haemophilia A subjected to synovectomy. Lancet 1988; 2: 1993.
  • 2
    Hedner U, Ingerslev J. Clinical use of recombinant FVIIa (rFVIIa). Transfus Sci 1998; 19: 16376.
  • 3
    Glazer S, Hedner U, Falch JF. Clinical update on the use of recombinant factor VIIa. Adv Exp Med Biol 1995; 386: 16374.
  • 4
    Ingerslev J. Efficacy and safety of recombinant factor VIIa in the prophylaxis of bleeding in various surgical procedures in hemophilic patients with factor VIII and factor IX inhibitors. Semin Thromb Hemost 2000; 26: 42532.
  • 5
    Négrier C, Hay CR. The treatment of bleeding in hemophilic patients with inhibitors with recombinant factor VIIa. Semin Thromb Hemost 2000; 26: 40712.
  • 6
    Erhardtsen E. Pharmacokinetics of recombinant activated factor VII (rFVIIa). Semin Thromb Hemost 2000; 26: 38591.
  • 7
    Key NS, Aledort LM, Beardsley D et al. Home treatment of mild to moderate bleeding episodes using recombinant factor VIIa in hemophiliacs with inhibitors. Thromb Haemost 1998; 80: 9128.
  • 8
    Ingerslev J, Thykjaer H, Kudsk Jensen O, Fredberg U. Home treatment with recombinant activated factor VII. results from one centre. Blood Coagul Fibrinolysis 1998; 9: S10710.
  • 9
    Laurian Y, Goudemand J, Négrier C et al. Use of recombinant activated factor VII as first line therapy for bleeding episodes in hemophiliacs with factor VII or IX inhibitors (NOSEPAC study). Blood Coagul Fibrinolysis 1998; 9: S1556.
  • 10
    Santagostino E, Gringeri A, Mannucci PM. Home treatment with recombinant activated factor VII in patients with factor VIII inhibitors: the advantages of early intervention. Br J Haematol 1999; 104: 226.
  • 11
    Lusher JM. Acute hemarthroses: the benefits of early versus late treatment with recombinant activated factor VII. Blood Coagul Fibrinolysis 2000; 11: S459.
  • 12
    Schulman S, Bech Jensen M, Varon D et al. Feasibility of using recombinant factor VIIa in continuous infusion. Thromb Haemost 1996; 75: 4326.
  • 13
    Mauser-Bunschoten EP, De Goede-Bolder A, Wielenga JJ, Levi M, Peerlinck K. Continuous infusion of recombinant factor VIIa in patients with hemophilia and inhibitors. Experience in the Netherlands and Belgium. Neth J Med 1998; 53: 24955.
  • 14
    Montoro JB, Altisent C, Pico M, Cabanas MJ, Vila M, Puig LL. Recombinant factor VIIa in continuous infusion during central line insertion in a child with factor VIII high-titer inhibitor. Haemophilia 1998; 4: 7625.
  • 15
    Vermylen J, Peerlinck K. Optimal care of inhibitor patients during surgery. Eur J Haematol 1998; 61 (Suppl. 63): 157.
  • 16
    McPherson J, Sutcharitchan P, Lloyd J, Street A, Nelleman JL, Yang SI. Experience with continuous infusion of recombinant activated factor VII in the Asia-Pacific region. Blood Coagul Fibrinolysis 2000; 11: S314.
  • 17
    Schulman S, D'Orion R, Martinowitz U et al. Experiences with continuous infusion of recombinant activated factor VII. Blood Coagul Fibrinolysis 1998; 9: S97101.
  • 18
    Schulman S. rFVIIa-CI group. Continuous infusion of recombinant factor VIIa in hemophilic patients with inhibitors: safety, monitoring and cost effectiveness. Semin Thromb Hemost 2000; 26: 4214.
  • 19
    Kenet G, Lubetsky A, Gitel S, Luboshitz J, Varon D, Martinowitz U. Treatment of bleeding episodes in patients with hemophilia and an inhibitor: comparison of two treatment protocols with recombinant activated factor VII. Blood Coagul Fibrinolysis 2000; 11: S358.
  • 20
    Hoffman M, Monroe DM 3rd, Roberts HR. Activated factor VII activates factors IX and X on the surface of activated platelets: thoughts on the mechanism of action of high-dose activated factor VII. Blood Coagul Fibrinolysis 1998; 9 (Suppl. 1): S615.
  • 21
    Blomback B, Carlsson K, Fatah K, Hessel B, Procyk R. Fibrin in human plasma: Gel architectures governed by rate and nature of fibrinogen activation. Thromb Res 1994; 75: 52138.
  • 22
    Gabriel DA, Muga K, Boothroyd EM. The effect of fibrin structure on fibrinolysis. J Biol Chem 1992; 267: 2425963.
  • 23
    Bajzar L. Thrombin activatable fibrinolysis inhibitor and an antifibrinolytic pathway. Arteriscler Thromb Vasc Biol 2000; 20: 25118.
  • 24
    Gallistl S, Cvirn G, Muntean W. Recombinant factor VIIa does not induce hypercoagulability in vitro. Thromb Haemost 1999; 81: 2459.
  • 25
    Baudo F, Redaelli R, Caimi TM, Mostarda G, Somaini G, De Cataldo F. The continuous infusion of recombinant activated factor VIIa (rFVIIa) in patients with factor VIII inhibitors activates the coagulation and fibrinolytic systems without clinical complications. Thromb Res 2000; 99: 214.
  • 26
    Hay CRM, Négrier C, Ludlam CA. The treatment of bleeding in acquired hemophilia with recombinant factor VIIa: a multicentre study. Thromb Haemost 1997; 78: 14637.
  • 27
    Roberts HR. Clinical experience with activated factor VII. focus on safety aspects. Blood Coag Fibrinolysis 1998; 9 (Suppl. 1): S1158.
  • 28
    Peerlink K, Vermylen J. Acute myocardial infarction following administration of recombinant activated factor VII (NovoSeven) in a patient with hemophilia A and inhibitor. Thromb Haemost 1999; 82: 17756.